Stocktoria

Bicara Therapeutics Inc. BCAX

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2024-09-13

Bicara Therapeutics Inc. statistics & valuation

Market cap$1.8B
P / B4.4×
Return on equity-34.4%
Return on capital-38.7%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202320242025
Operating margin (%)
202320242025
Return on equity (%)
-13.80% -34.40% 202320242025
Shares outstanding
580.1M 16.81B 54.68B 202320242025
Net debt ($)
202320242025
Share buybacks ($)
202320242025
Return on assets (%)
-22.20% -13.30% -32.00% 202320242025
Free cash flow margin (%)
202320242025
Debt / equity (×)
202320242025
EPS ($)
-$89.61 -$4.05 -$2.52 202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023
Return on assets-32.0%-13.3%-22.2%
Return on equity-34.4%-13.8%34.9%
Current ratio14.5827.9315.32

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.